<DOC>
	<DOCNO>NCT00351286</DOCNO>
	<brief_summary>To prove combination L-citrulline simvastatin lead great improvement symptom peripheral arterial disease ( PAD ) simvastatin alone evaluate oral L- citrulline placebo simvastatin improvement treadmill walk distance patient , 40–75 year age , PAD intermittent claudication .</brief_summary>
	<brief_title>Efficacy Study Oral L-Citrulline Patients Taking Simvastatin With Peripheral Arterial Disease</brief_title>
	<detailed_description>The primary objective study prove combination L-citrulline simvastatin lead great improvement symptom PAD simvastatin alone . This accomplish evaluate efficacy orally administer L-citrulline placebo background therapy simvastatin improvement treadmill absolute claudication walk distance ( ACWD ) patient , 40–75 year age , PAD intermittent claudication Fontaine stage II symptom-limited treadmill walk distance . Secondary objective include compare combination therapy simvastatin alone improvement treadmill pain-free walking distance ( PFWD ) ischemic window . Other secondary objective include evaluate safety tolerability L-citrulline alone combine simvastatin patient population assess effect treatment quality life ( QOL ) measure two QOL instrument .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Male female , 40–75 year age 2 . If female , postmenopausal past year , surgically sterile ( i.e. , tubal ligation , hysterectomy ) , use adequate method birth control ( i.e. , oral contraceptive , double barrier method , IUD cover , sterilized partner , method deem appropriate Investigator ) 3 . If male capable father child , use adequate method birth control ( i.e. , condom partner use adequate method birth control ) 4 . Peripheral arterial disease stable , reproducible , intermittent claudication symptomlimited treadmill walk distance least 6 month duration 5 . Rest anklebrachial index ( ABI ) ≤0.90 10 mm Hg decrease ankle pressure 1 minute complete ETT 6 . ACWD standardize ( SkinnerGardner protocol ) ETT ≥50 ( 164 foot ) ≤300 ( 984 foot ) determine average result two consecutive ETTs perform least 7 day apart screen phase ( Fontaine stage II ) 7 . ACWD variability &lt; 25 % two consecutive ETTs perform least 7 day apart screen phase . The percent variability calculate difference two walking distance divide great two walk distance multiply 100 % . If variability exceed 25 % third ETT may perform variability second third test use determine baseline inclusion criterion 8 . Willingness receive dietary counseling follow lowcholesterol diet study 9 . Ability give write informed consent sign write informed consent form approve Investigator ’ Independent Ethics Committee ( IEC ) 1 . Critical limb ischemia ( define presence rest pain require analgesic 2 week presence low limb ulcer gangrene ) 2 . Coronary artery peripheral artery angioplasty surgical limb arterial bypass within last 3 month 3 . Any previous amputation lower limbs 4 . Anticipated requirement surgical percutaneous revascularization within 3 month randomization 5 . Currently participate supervise exercise regimen 6 . Stroke , myocardial infarction , deepvein thrombosis within last 3 month 7 . Nonatherosclerotic PAD ( e.g. , thromboangiitis obliterans ) 8 . Known abdominal aortic aneurysm ≥4.5 cm 9 . Unstable angina pectoris within last 3 month 10 . Congestive heart failure ( New York Heart Association Class III IV ) despite treatment 11 . Severe , uncontrolled hypertension ( sit systolic blood pressure &gt; 180 mm Hg sit diastolic blood pressure &gt; 95 mm Hg ) 12 . Anemia ( hemoglobin &lt; 10 g/dL woman 11 g/dL men ) clinically significant bleeding episode within last year 13 . Abnormal platelet count ( platelet &gt; 150,000/mm3 &lt; 60,000/mm3 ) 14 . Type I diabetes mellitus Type II diabetes mellitus accompany diabetic peripheral neuropathy 15 . Morbid obesity ( body mass index &gt; 40 kg/m2 ) 16 . Severe renal insufficiency ( creatinine &gt; 221 µmol/L ( 2.5 mg/dL ) ) 17 . Severe hepatic insufficiency ( ALT [ SGPT ] AST [ SGOT ] ≥ 3x upper limit normal two separate test 18 . Any disorder would affect interpretation ETT result 19 . Use medication allow discontinue study 20 . Participation investigational drug device study within previous 30 day 21 . Underlying disease PAD result life expectancy le 1 year 22 . If female , breast feeding , pregnancy confirm positive serum pregnancy test , use inadequate birth control 23 . Other condition could impair informed consent compliance</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>peripheral arterial disease</keyword>
	<keyword>peripheral vascular disease</keyword>
	<keyword>claudication</keyword>
</DOC>